{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-a/management/prevention-of-infection-with-hepatitis-a/","result":{"pageContext":{"chapter":{"id":"1a3874e3-8562-5ca6-8c97-4d9a2a009e75","slug":"prevention-of-infection-with-hepatitis-a","fullItemName":"Scenario: Prevention of infection with hepatitis A","depth":2,"htmlHeader":"<!-- begin field f5f0db48-6f20-4e03-ae9c-b9ea5b80fb94 --><h2>Scenario: Prevention of infection with hepatitis A</h2><!-- end field f5f0db48-6f20-4e03-ae9c-b9ea5b80fb94 -->","summary":"Covers who should be offered pre-exposure vaccination, who should be offered pre-vaccination testing, and hygiene advice for people at high risk.","htmlStringContent":"<!-- begin item ded06b7d-f8c5-4d16-84af-a51ad03c7de6 --><!-- begin field a0e39dce-1abc-402c-ad98-acbc015a3266 --><p>From birth onwards.</p><!-- end field a0e39dce-1abc-402c-ad98-acbc015a3266 --><!-- end item ded06b7d-f8c5-4d16-84af-a51ad03c7de6 -->","topic":{"id":"29ac65ab-afdd-58a1-bb07-9c101977d24d","topicId":"580cfa7a-647b-439a-8f8c-493cb6bd4332","topicName":"Hepatitis A","slug":"hepatitis-a","lastRevised":"Last revised in January 2021","chapters":[{"id":"d47cd8cf-fe05-5aa4-997b-01a20519d12f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bbe6550-f4f5-5279-9e9e-04b38f9dc672","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75791cbd-6d69-555e-83e8-9ac8cca25c50","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c0ae1a2d-febe-5ec7-821a-0616062456ee","slug":"changes","fullItemName":"Changes"},{"id":"434eb73d-f60d-5f1f-ba10-5aa77d904da1","slug":"update","fullItemName":"Update"}]},{"id":"242c9e8c-5867-5598-9168-62160e8ae293","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"6c2f4656-f9e8-56be-aa43-3f6a9aa45aa8","slug":"goals","fullItemName":"Goals"},{"id":"71c0a726-22c7-568b-b925-d10cc97ace3a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"70e8a1cd-fd5b-50d7-8ce4-b6f29981218d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"37bb7a58-62c9-52be-b97c-7b99f8317f12","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"badbd40f-9ce6-5f8a-9f65-8be03bc8d3fe","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ed9f7297-1f33-5365-8e4f-3844542af45d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a11034-e31c-5039-8ca7-b463c00b2039","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a2206363-5f44-5348-b469-07b49a6a9647","slug":"definition","fullItemName":"Definition"},{"id":"dd1ca873-1bf9-500d-a574-fc92c8589e62","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bdd89354-2f0b-564c-b589-cb043e32b99c","slug":"transmission","fullItemName":"Transmission"},{"id":"8e72bb81-12fd-5a0e-976b-d18d62788974","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ab3f5823-00db-5e27-a434-c323c357ab02","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e879b74c-3d75-59c5-806e-4b39a6e72901","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"94f8b729-5e94-57ee-b96e-ca1561614640","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"6b32fed7-c15e-5976-adc6-692994cbab9e","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"2503640c-54cf-53e1-b29c-fc9c19cbd52a","slug":"investigations","fullItemName":"Investigations"},{"id":"88a35298-3760-53b6-b4ff-b9e0677b4df3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9ba7b244-14ec-5fd1-9b2b-151b9c48bfab","fullItemName":"Management","slug":"management","subChapters":[{"id":"1a3874e3-8562-5ca6-8c97-4d9a2a009e75","slug":"prevention-of-infection-with-hepatitis-a","fullItemName":"Scenario: Prevention of infection with hepatitis A"},{"id":"49c1d671-61dd-5a60-974f-069b03d80d11","slug":"managing-hepatitis-a-infection","fullItemName":"Scenario: Managing hepatitis A infection"},{"id":"449ffa79-3397-54a1-a4d5-0efa55ee889f","slug":"contact-with-hepatitis-a","fullItemName":"Scenario: Contact with hepatitis A"}]},{"id":"8ffd203a-96db-5a38-a7bd-0186b97b6600","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"7d022e5d-ab4e-50bf-b90f-5611cf3a17db","slug":"hepatitis-a-vaccine","fullItemName":"Hepatitis A vaccine"},{"id":"7d0e86fd-3666-5a09-b539-4497227285ee","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0ee2b156-78a9-52f6-ab80-fff22c46ff66","slug":"anti-emetics","fullItemName":"Anti-emetics"},{"id":"508e578c-aa68-5cdb-aa90-ef8889919c08","slug":"anti-pruritics","fullItemName":"Anti-pruritics"}]},{"id":"bf6b787f-fbb7-5d8d-bd85-cfe063c76fcd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e0bba353-de5a-55b9-9171-a677ecc4b97a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2571e87f-4ad0-5f6d-8c0e-8c9c86054278","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"94bd9363-8cd1-5ba6-8fd3-11f5a3ce29dd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2db0f1a2-7d4b-5fd2-a8bf-db32553e5b89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"29233885-dedb-5c3b-ba7e-1aae299ecfe2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0a3a365f-c89a-5f1e-8ce5-1078ade19779","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1afe9613-76a4-50b9-8941-c2a2ebec23cc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9ba7b244-14ec-5fd1-9b2b-151b9c48bfab","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"c0993351-34fc-51c7-83d2-d5603dd51390","slug":"hepatitis-a-vaccination","fullItemName":"Hepatitis A vaccination","depth":3,"htmlHeader":"<!-- begin field 66bedd61-534e-49e6-9cc3-00ee212b135d --><h3>Who should be offered vaccination for hepatitis A?</h3><!-- end field 66bedd61-534e-49e6-9cc3-00ee212b135d -->","summary":null,"htmlStringContent":"<!-- begin item 893c0c09-cba8-48f2-bcad-4bc386ad12bf --><!-- begin field 6d7046b6-c3c2-48bb-86c2-18bb1552df7b --><ul><li><strong>Vaccination is indicated for people considered to be at high risk of acquiring hepatitis A infection, and/or those at the highest risk of complications, including:</strong><ul><li>People travelling to or going to reside in areas of high or intermediate prevalence — vaccine should preferably be given at least two weeks before departure, but may still provide some protection when given up to the day of departure.</li><li>People with chronic liver disease (including hepatitis B or C infection) — risk of complications is increased.</li><li>People receiving plasma-derived clotting factors to treat haemophilia.</li><li>Injecting drug users.</li><li>Men who have sex with men with multiple sexual partners.</li><li>People at occupational risk.</li><li>For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-a/background-information/risk-factors/\">risk factors</a> for hepatitis A.</li></ul></li><li><strong>Consider pre-vaccination serology testing</strong><strong> for hepatitis A virus immunoglobulin G</strong> (HAV-IgG) to check for immunity in people from highly endemic areas, those with a prior history of hepatitis or jaundice, and in men who have sex with men.<ul><li>If immunity to hepatitis A is demonstrated following initial serology testing, there is no need to vaccinate the person. For information on hepatitis serology testing, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-a/diagnosis/investigations/\">investigations</a>.</li></ul></li><li><strong>For all other people at high risk, who are not known to be immune, </strong>offer hepatitis A vaccination.<ul><li>The usual schedule for monovalent hepatitis A vaccines is a single dose and then a booster dose 6-12 months later if the person remains at long-term risk of contracting hepatitis A.</li><li>Some vaccines combine hepatitis A with other antigens (typhoid or hepatitis B) and may require different schedules.</li><li>Pregnancy is not a contraindication to receiving the hepatitis A vaccine where clinically indicated.</li></ul></li><li>For detailed information on the available hepatitis A vaccines, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-a/prescribing-information/\">Prescribing information</a>.<ul><li>Note: combined hepatitis A and B vaccines should be considered for people at risk of both infections. For further details, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hepatitis-b/\">Hepatitis B</a>.</li></ul></li></ul><!-- end field 6d7046b6-c3c2-48bb-86c2-18bb1552df7b --><!-- end item 893c0c09-cba8-48f2-bcad-4bc386ad12bf -->","subChapters":[{"id":"58996e92-21c6-583e-8d57-789a848c82ec","slug":"basis-for-recommendation-321","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 753a2210-a3d4-4047-a7d3-c1bc02d43830 --><h4>Basis for recommendation</h4><!-- end field 753a2210-a3d4-4047-a7d3-c1bc02d43830 -->","summary":null,"htmlStringContent":"<!-- begin item 321de436-7be9-4cb1-9682-7d28440595aa --><!-- begin field f524b0be-ed48-4b4b-b2bd-14a694076e0f --><p>The information on vaccination against hepatitis A is largely based on expert opinion within the Public Health England (PHE) publication <em>Immunisation against infectious diseases</em> (the 'Green Book'), chapter 17 <em>Hepatitis A</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2013b</a>].</p><h5>Pre-vaccination testing of particular high-risk groups</h5><ul><li>The recommendation to consider pre-vaccination testing for people from areas of high endemicity of hepatitis A, or with a past history of jaundice or hepatitis, derives from a 2009 review article which states that it may be cost-effective to screen high-risk people to check whether they are already hepatitis A immune [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">Steele et al, 2009</a>].</li><li>The recommendation to consider pre-vaccination testing for men who have sex with men (MSM) is based on a guidance from BASHH relating to management in a sexual health setting, which states that 'screening for pre-existing hepatitis A exposure before vaccination has been found to be cost-effective in one study and therefore may be performed, depending on other factors such as funding and clinic access' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">BASHH, 2017</a>]. The study being referred to within the guideline is a 2007 audit of different vaccination strategies for MSM attending a large sexual health clinic in London, which concluded that screening MSM for hepatitis A virus immunoglobulin G (HAV-IgG) in an area of relatively low prevalence of hepatitis A, is the most cost-effective approach [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">O'Riordan et al, 2007</a>].</li><li>It is notable, however, that the same BASHH guideline estimated the cost of serology testing in 2017 to be similar to that of vaccination (around £10 to £20) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">BASHH, 2017</a>], and CKS therefore pragmatically recommends that clinical judgement should be exercised and that any decision to carry out pre-vaccination serology should also be based on patient factors (such as the likelihood of prior immunity, the urgency of requirement for protection, the individual risks and benefits of vaccination, and the chance that the person may not return for a second appointment) rather than primarily on cost-effectiveness.</li></ul><!-- end field f524b0be-ed48-4b4b-b2bd-14a694076e0f --><!-- end item 321de436-7be9-4cb1-9682-7d28440595aa -->","subChapters":[]}]},{"id":"0b85e185-d08c-54fa-b16a-5527fccdc38a","slug":"advice-for-people-at-high-risk-of-infection","fullItemName":"Advice for people at high risk of infection","depth":3,"htmlHeader":"<!-- begin field f6b1846c-bfb9-4ea4-8799-be1fb6bf12fc --><h3>What advice should I give to people at high risk of hepatitis A infection?</h3><!-- end field f6b1846c-bfb9-4ea4-8799-be1fb6bf12fc -->","summary":null,"htmlStringContent":"<!-- begin item 60fbbfb9-67fd-46ac-8532-b077e80532f5 --><!-- begin field 9a21ac4f-9e17-4988-bb8b-b28a2ff17cf9 --><p><strong>In order to avoid hepatitis A infection, advise people:</strong></p><ul><li><strong>Engaging in activities that pose a <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-a/background-information/risk-factors/\">high risk</a> of infection via the faecal-oral route to:</strong><ul><li>Practice safe sex to reduce the risk of sexual acquisition/transmission.</li><li>Avoid reusing/sharing injecting equipment.</li><li>Thoroughly wash their hands before food preparation and eating.</li><li>Ensure good personal hygiene.</li></ul></li><li><strong>Travelling to moderately or highly endemic areas to:</strong><ul><li>Avoid food and water potentially contaminated by human faeces — in particular, foods grown close to the ground (such as strawberries and salad vegetables), and under-cooked or raw molluscs that feed by filtering large volumes of sewage-polluted waters (such as mussels, oysters and clams). For additional information on the prevention of food and water-borne diseases, see the <a href=\"https://travelhealthpro.org.uk/factsheet/44/food-and-water-hygiene\" data-hyperlink-id=\"aa392ef2-1806-4197-b939-aaf5015517ba\">NaTHNaC website</a>.</li></ul></li><li><strong>At occupational risk of infection to:</strong><ul><li>Use appropriate protective gloves, boots, and face protection, as required within their individual role.</li></ul></li><li>For more information on advice on how people with hepatitis A can reduce the risk of transmission to others, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-a/management/managing-hepatitis-a-infection/#managing-hepatitis-a-infection\">Information and advice</a>.</li></ul><!-- end field 9a21ac4f-9e17-4988-bb8b-b28a2ff17cf9 --><!-- end item 60fbbfb9-67fd-46ac-8532-b077e80532f5 -->","subChapters":[{"id":"4a4d9a92-4ac9-5718-b186-4082f5876be0","slug":"basis-for-recommendation-43a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f2488b69-273e-4e37-9fc2-79e4eba9f2ce --><h4>Basis for recommendation</h4><!-- end field f2488b69-273e-4e37-9fc2-79e4eba9f2ce -->","summary":null,"htmlStringContent":"<!-- begin item 43a1e1de-4c96-4f5b-8adf-d0ca6848c60b --><!-- begin field 7774ae7a-1ca9-472b-8c07-793e97dd073a --><p>The recommendations on advice to minimise a person's risk of acquiring hepatitis A are based on expert opinion from Public Health England (PHE) within the publication <em>Immunisation against infectious diseases</em> (the 'Green Book'), chapter 17 <em>Hepatitis A</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2013b</a>] and the guideline <em>Public health control and management of hepatitis A</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2017</a>], as well as the British Association of Sexual Health and HIV (BASHH) <em>National Guidelines for the Management of the Viral Hepatitides</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">BASHH, 2017</a>], and the National Travel Health Network and Centre (NaTHNac) guideline <em>Hepatitis A</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">NaTHNaC, 2019</a>].</p><!-- end field 7774ae7a-1ca9-472b-8c07-793e97dd073a --><!-- end item 43a1e1de-4c96-4f5b-8adf-d0ca6848c60b -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}